Bladder cancer research
Comparative proteomics research has identified proteins in the profile of muscle-invasive bladder cancer cells that could be used in biomarker panels for screening and targeted therapies.
Comparative proteomics research has identified proteins in the profile of muscle-invasive bladder cancer cells that could be used in biomarker panels for screening and targeted therapies.
The research, published in Cancer Cell International,1 aimed to facilitate candidate biomarkers selection and improve network-based multi-target therapy by using comparative proteomics on muscle-invasive bladder transitional cell carcinoma.
Laser capture microdissection was used to harvest the cells, which were then analysed using two-dimensional liquid chromatography–tandem mass spectrometry. This allowed the researchers to identify the proteome expression profile of the cells, which was then analysed further using bioinformatics tools.
Several pathways were found to exhibit significant differences between cancer and normal cells. The study identified the proteome expression of both the cancer cells and the normal urothelial cells, which the researchers reports will provide information for subcellular pattern research of cancer and offer candidate proteins for biomarker panels and targeted therapies.
1. H.T. Niu et al., Cancer Cell Int., 11(17), 1–17 (2011).
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
